Trials / Completed
CompletedNCT04394845
A Study of the Biodistribution and Safety of [18F]GTP1 in Healthy Japanese Participants
Assessment of the Biodistribution and Safety of [18F]GTP1 in Healthy Japanese Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Genentech, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the biodistribution, safety and tolerability of a single dose of \[18F\]GTP1 as a tau targeted radiopharmaceutical in healthy Japanese participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | [18F]GTP1 | \[18F\]GTP1 IV bolus injection of up to 370 megabecquerel (MBq) (10 millicurie \[mCi\]), with a maximum drug mass dose of 10 microgram (μg). |
Timeline
- Start date
- 2020-08-11
- Primary completion
- 2020-10-09
- Completion
- 2020-10-09
- First posted
- 2020-05-19
- Last updated
- 2021-11-03
- Results posted
- 2021-11-03
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04394845. Inclusion in this directory is not an endorsement.